This Week in Cardiology — Oct 26, 2026
Generated Oct 27, 2026 · 11:12
The week's practice-changing Cardiology research, summarized for clinicians.
If the audio fails to play, refresh the page to renew the link.
Get next week’s Cardiology briefing — free.
In your podcast app, or readable in your inbox with the audio one tap away.
Advanced Subclinical Atherosclerosis in Young Individuals and Risk of Mortality Over 30 Years: The Coronary Artery Calcium Consortium.
Adults aged 30 to 45 with coronary calcium above the 90th percentile had roughly double all-cause and nearly fourfold coronary mortality over two decades versus those with zero calcium.
JAMA Cardiology · 2026 · PubMed
This week’s papers
- 01
A Female-Specific Life Course Approach to the Prevention and Management of Cardiovascular Disease: A Presidential Advisory From the American Heart Association, American Academy of Pediatrics, American College of Obstetricians and Gynecologists, and Society for Maternal-Fetal Medicine.
Four societies propose a Female Life Stage framework based on hormonal transitions to unify fragmented cardiovascular prevention for girls and women, setting priorities for implementation, research and policy.
Khan SS et al. · Circulation · 2026
From the briefingThe presidential advisory led by Khan lays out the rationale for what the groups call the Female Life Stage framework [1], and the companion scientific statement, also led by Khan, crosswalks existing society guidelines and offers consensus guidance for each stage [2]. The framework defines four stages driven by changes in sex hormones: perimenarche, ovarian cycling, perimenopause, and postmenopause, with pregnancy treated as a modifying event when risk may be unmasked, for example through adverse pregnancy outcomes. The central argument is that care for girls and women is fragmented across pediatrics, obstetrics, primary care, cardiology, endocrinology and more, and that inconsistent guidelines create missed opportunities. These are consensus documents rather than new trial data, so their weight lies in aligning four societies around a shared structure; the authors themselves call for workflow changes, clinician education, and research to fill evidence gaps.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 02
Consensus Guidance for the Female-Specific Prevention and Management of Cardiovascular Disease: A Scientific Statement From the American Heart Association, American Academy of Pediatrics, American College of Obstetricians and Gynecologists, and Society for Maternal-Fetal Medicine.
A multisociety statement crosswalks existing guidelines and offers consensus guidance across four female life stages, treating pregnancy as an event that can unmask future cardiovascular risk.
Khan SS et al. · Circulation · 2026
From the briefingThe presidential advisory led by Khan lays out the rationale for what the groups call the Female Life Stage framework [1], and the companion scientific statement, also led by Khan, crosswalks existing society guidelines and offers consensus guidance for each stage [2]. The framework defines four stages driven by changes in sex hormones: perimenarche, ovarian cycling, perimenopause, and postmenopause, with pregnancy treated as a modifying event when risk may be unmasked, for example through adverse pregnancy outcomes. The central argument is that care for girls and women is fragmented across pediatrics, obstetrics, primary care, cardiology, endocrinology and more, and that inconsistent guidelines create missed opportunities. These are consensus documents rather than new trial data, so their weight lies in aligning four societies around a shared structure; the authors themselves call for workflow changes, clinician education, and research to fill evidence gaps.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 03
Advanced Subclinical Atherosclerosis in Young Individuals and Risk of Mortality Over 30 Years: The Coronary Artery Calcium Consortium.
Adults aged 30 to 45 with coronary calcium above the 90th percentile had roughly double all-cause and nearly fourfold coronary mortality over two decades versus those with zero calcium.
Choi S et al. · JAMA Cardiology · 2026
From the briefingStaying with risk identification, JAMA Cardiology published a cohort analysis from the Coronary Artery Calcium Consortium led by Choi, looking at nearly thirteen thousand adults aged 30 to 45 who had clinically indicated calcium scans and were followed for a median of more than twenty two years [3]. Roughly seven in ten of these young adults had a calcium score of zero, while about one in eight had a score above the ninetieth percentile for their age. After adjusting for traditional risk factors, young adults in that top group had close to double the risk of dying from any cause, about two and a half times the risk of cardiovascular death, and nearly four times the risk of coronary death compared with those at zero. In modeled thirty-year terms, coronary mortality was about three percent versus well under one percent. The cohort was referral-based and heavily male, around three quarters, so generalizability to unselected young adults and to women is limited, and the study does not test whether intensifying treatment changes outcomes. Still, it provides some of the longest follow-up available for premature calcification, and the authors conclude it supports considering this phenotype for intensified prevention.
If you only have time for one paper this week, make it the Coronary Artery Calcium Consortium analysis in JAMA Cardiology [3]. It offers rare multi-decade outcome data on calcification in adults under 45, reopening the question of how early and how intensively prevention should start in people whose risk calculators look reassuring.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 04
Lipoprotein(a) and Risk Stratification for Atherosclerotic Cardiovascular Disease Across the Cardiovascular-Kidney-Metabolic Continuum.
In UK Biobank, elevated lipoprotein(a) raised atherosclerotic risk by about 30 percent at every cardiovascular-kidney-metabolic stage, with absolute excess risk largest in people at advanced stages.
Fang Y et al. · Journal of the American Heart Association · 2026
From the briefingThe Journal of the American Heart Association adds a complementary angle with a UK Biobank analysis led by Fang, covering about a third of a million people free of cardiovascular disease and followed for around fifteen years [4]. Elevated lipoprotein(a), defined as 125 nanomoles per liter or higher, was linked to roughly a thirty percent higher risk of atherosclerotic events even after accounting for LDL cholesterol and cardiovascular-kidney-metabolic stage. The more clinically useful observation is about absolute risk: the excess risk attributable to high lipoprotein(a) was tiny, about a quarter of a percentage point over ten years, in people at stage zero, but rose to about two percentage points in those at stage three. People with both advanced stage and high lipoprotein(a) had more than three times the risk of the healthiest group. This is observational, largely European-ancestry data, but it strengthens the case that lipoprotein(a) matters most, in absolute terms, for people already accumulating metabolic and kidney risk.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 05
Sodium-Glucose Cotransporter 2 Inhibitor Use and Levels of Hemoglobin, Markers of Iron Metabolism, and Erythropoiesis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
Across 85 randomized trials, SGLT2 inhibitors raised hemoglobin by about 0.6 g/dL with higher erythropoietin and lower transferrin saturation, small changes of unclear clinical significance.
Yang Y et al. · JAMA · 2026
From the briefingOur second theme is drug therapy, where two systematic reviews refine what we know about familiar and emerging agents. In JAMA, Yang and colleagues pooled 85 randomized trials with more than seventy thousand participants to quantify the long-observed hemoglobin rise with SGLT2 inhibitors [5]. Compared with control, these drugs raised hemoglobin by about 0.6 grams per deciliter and hematocrit by just over two percentage points, accompanied by a small rise in erythropoietin and a small fall in transferrin saturation, a pattern consistent with stimulated red cell production drawing on iron stores. The authors are explicit that these are small changes and that their clinical significance is unclear, so the finding mainly helps clinicians interpret a modest hemoglobin rise in a treated patient rather than suggesting a new indication.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 06
Efficacy and Safety of Pharmacologic Therapies in Nonobstructive Hypertrophic Cardiomyopathy: A Systematic Review.
Across 29 trials in nonobstructive hypertrophic cardiomyopathy, myosin inhibitors improved structure and biomarkers with variable symptom benefit, while SGLT2 inhibitors helped diabetic patients; no therapy is yet established.
Patel S et al. · Journal of the American Heart Association · 2026
From the briefingSGLT2 inhibition also surfaces in a Journal of the American Heart Association systematic review led by Patel on nonobstructive hypertrophic cardiomyopathy, a group making up about a third of patients with the disease and with no approved disease-modifying therapy [6]. Across 29 trials and nine drug classes, cardiac myosin inhibitors reduced hypertrophy and biomarkers and improved diastolic function, but gains in exercise capacity and symptoms were inconsistent. SGLT2 inhibitors showed concordant improvements in diastolic function, atrial remodeling and functional status, though only in patients with coexisting type 2 diabetes. Angiotensin receptor blockers showed structural signals without consistent functional benefit, while mineralocorticoid antagonists and sacubitril-valsartan were largely neutral, and the metabolic modulator ninerafaxstat helped patients with greater symptom burden. This is a narrative synthesis of mostly small studies, so it maps the landscape rather than establishing any therapy, and ongoing trials will be decisive.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 07
Acute heart failure in emergency settings.
A consensus document for prehospital and emergency care emphasizes rapid classification of acute heart failure into four phenotypes to guide early treatment, triage and disposition, noting major evidence gaps.
Miró Ò et al. · European Heart Journal · 2026
From the briefingOur final theme covers acute care and procedures, where timing and technique are the recurring questions. The European Heart Journal published a consensus document led by Miró on acute heart failure in emergency settings, spanning prehospital services and the emergency department [7]. Its organizing idea is rapid phenotyping into acute decompensated heart failure, acute pulmonary oedema, isolated right ventricular failure, or cardiogenic shock to guide early treatment and triage, and it reviews biomarkers, imaging, ventilatory support, diuretic and vasodilator strategies, and early initiation or continuation of guideline-directed therapy. The authors acknowledge major gaps, particularly the need for pragmatic prehospital trials.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 08
Not All Strokes Are Equal: Phenotype-Dependent Surgical Timing in Infective Endocarditis.
In endocarditis surgery after stroke, early postoperative neurologic risk was driven by hemorrhagic and septic embolic strokes, whereas ischemic strokes showed no clear association with surgical timing.
Kubi B et al. · Journal of the American Heart Association · 2026
From the briefingA two-center study in the Journal of the American Heart Association, led by Kubi, tackles a perennial dilemma: when to operate on left-sided infective endocarditis after a stroke [8]. Among 322 surgical patients, postoperative cerebrovascular events fell from about one in five with surgery inside a week to around one in ten with later surgery, and each day of delay modestly lowered the odds. That excess risk, however, was driven by intraparenchymal and subarachnoid hemorrhage and septic emboli. Ischemic strokes showed no meaningful timing effect, and operative mortality was numerically lowest with early surgery, though not significantly so. Meanwhile, about one in ten patients awaiting surgery embolized again. The authors suggest routine delay after ischemic stroke may be unnecessary while a short delay of about a week may be reasonable for hemorrhagic and septic embolic subtypes. This is retrospective, and the hemorrhagic subgroups are small, but it gives phenotype-level data where guidance has often been blunt.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 09
Sirolimus-Coated Balloon Angioplasty for Femoropopliteal Artery Disease Without Tissue Loss: A Secondary Analysis of the SirPAD Trial.
In femoropopliteal disease without tissue loss, sirolimus-coated balloons were associated with lower one-year target-lesion revascularization, 17 versus 27 percent, in a descriptive, non-confirmatory secondary analysis.
Tsaftaridis N et al. · Journal of the American College of Cardiology · 2026
From the briefingIn peripheral intervention, the Journal of the American College of Cardiology published a secondary analysis of the randomized SirPAD trial led by Tsaftaridis, focusing on 597 patients with femoropopliteal disease and no tissue loss [9]. At one year, repeat revascularization of the target lesion occurred in 17 percent with a sirolimus-coated balloon versus 27 percent with an uncoated balloon, about a ten-point absolute reduction, and major adverse limb events were roughly halved. Mortality was similar. The authors stress these findings are descriptive rather than confirmatory, so this is supportive but not definitive evidence for the claudication population.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 10
The evolution and future of conduction system pacing.
Left bundle branch area pacing has become the dominant physiological pacing approach, while Bachmann bundle area pacing is an emerging atrial strategy that may help prevent atrial fibrillation.
Lee SR et al. · Nature Reviews Cardiology · 2026
From the briefingRounding out the theme, Nature Reviews Cardiology carries a review by Lee and colleagues on conduction system pacing [10]. It traces the shift from right ventricular apical pacing, with its risk of pacing-induced cardiomyopathy, through His bundle pacing to left bundle branch area pacing, now the dominant modality because of better success and lead stability, with applications from bradycardia to resynchronization. It also introduces Bachmann bundle area pacing as an atrial counterpart that may reduce interatrial delay and possibly atrial fibrillation, an idea the authors flag as needing more evidence.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
The full briefing
This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice.
Welcome to This Week in Cardiology. This week we're covering 10 notable papers spanning cardiovascular prevention and risk stratification across the life course, therapeutic signals in heart failure and cardiomyopathy, and timing and technique in acute and procedural care. Let's dive in.
We start with prevention, where several papers this week ask how to identify risk earlier and more precisely. Circulation published a matched pair of documents from the American Heart Association together with the American Academy of Pediatrics, the American College of Obstetricians and Gynecologists, and the Society for Maternal-Fetal Medicine. The presidential advisory led by Khan lays out the rationale for what the groups call the Female Life Stage framework [1], and the companion scientific statement, also led by Khan, crosswalks existing society guidelines and offers consensus guidance for each stage [2]. The framework defines four stages driven by changes in sex hormones: perimenarche, ovarian cycling, perimenopause, and postmenopause, with pregnancy treated as a modifying event when risk may be unmasked, for example through adverse pregnancy outcomes. The central argument is that care for girls and women is fragmented across pediatrics, obstetrics, primary care, cardiology, endocrinology and more, and that inconsistent guidelines create missed opportunities. These are consensus documents rather than new trial data, so their weight lies in aligning four societies around a shared structure; the authors themselves call for workflow changes, clinician education, and research to fill evidence gaps.
Staying with risk identification, JAMA Cardiology published a cohort analysis from the Coronary Artery Calcium Consortium led by Choi, looking at nearly thirteen thousand adults aged 30 to 45 who had clinically indicated calcium scans and were followed for a median of more than twenty two years [3]. Roughly seven in ten of these young adults had a calcium score of zero, while about one in eight had a score above the ninetieth percentile for their age. After adjusting for traditional risk factors, young adults in that top group had close to double the risk of dying from any cause, about two and a half times the risk of cardiovascular death, and nearly four times the risk of coronary death compared with those at zero. In modeled thirty-year terms, coronary mortality was about three percent versus well under one percent. The cohort was referral-based and heavily male, around three quarters, so generalizability to unselected young adults and to women is limited, and the study does not test whether intensifying treatment changes outcomes. Still, it provides some of the longest follow-up available for premature calcification, and the authors conclude it supports considering this phenotype for intensified prevention.
The Journal of the American Heart Association adds a complementary angle with a UK Biobank analysis led by Fang, covering about a third of a million people free of cardiovascular disease and followed for around fifteen years [4]. Elevated lipoprotein(a), defined as 125 nanomoles per liter or higher, was linked to roughly a thirty percent higher risk of atherosclerotic events even after accounting for LDL cholesterol and cardiovascular-kidney-metabolic stage. The more clinically useful observation is about absolute risk: the excess risk attributable to high lipoprotein(a) was tiny, about a quarter of a percentage point over ten years, in people at stage zero, but rose to about two percentage points in those at stage three. People with both advanced stage and high lipoprotein(a) had more than three times the risk of the healthiest group. This is observational, largely European-ancestry data, but it strengthens the case that lipoprotein(a) matters most, in absolute terms, for people already accumulating metabolic and kidney risk.
Our second theme is drug therapy, where two systematic reviews refine what we know about familiar and emerging agents. In JAMA, Yang and colleagues pooled 85 randomized trials with more than seventy thousand participants to quantify the long-observed hemoglobin rise with SGLT2 inhibitors [5]. Compared with control, these drugs raised hemoglobin by about 0.6 grams per deciliter and hematocrit by just over two percentage points, accompanied by a small rise in erythropoietin and a small fall in transferrin saturation, a pattern consistent with stimulated red cell production drawing on iron stores. The authors are explicit that these are small changes and that their clinical significance is unclear, so the finding mainly helps clinicians interpret a modest hemoglobin rise in a treated patient rather than suggesting a new indication.
SGLT2 inhibition also surfaces in a Journal of the American Heart Association systematic review led by Patel on nonobstructive hypertrophic cardiomyopathy, a group making up about a third of patients with the disease and with no approved disease-modifying therapy [6]. Across 29 trials and nine drug classes, cardiac myosin inhibitors reduced hypertrophy and biomarkers and improved diastolic function, but gains in exercise capacity and symptoms were inconsistent. SGLT2 inhibitors showed concordant improvements in diastolic function, atrial remodeling and functional status, though only in patients with coexisting type 2 diabetes. Angiotensin receptor blockers showed structural signals without consistent functional benefit, while mineralocorticoid antagonists and sacubitril-valsartan were largely neutral, and the metabolic modulator ninerafaxstat helped patients with greater symptom burden. This is a narrative synthesis of mostly small studies, so it maps the landscape rather than establishing any therapy, and ongoing trials will be decisive.
Our final theme covers acute care and procedures, where timing and technique are the recurring questions. The European Heart Journal published a consensus document led by Miró on acute heart failure in emergency settings, spanning prehospital services and the emergency department [7]. Its organizing idea is rapid phenotyping into acute decompensated heart failure, acute pulmonary oedema, isolated right ventricular failure, or cardiogenic shock to guide early treatment and triage, and it reviews biomarkers, imaging, ventilatory support, diuretic and vasodilator strategies, and early initiation or continuation of guideline-directed therapy. The authors acknowledge major gaps, particularly the need for pragmatic prehospital trials.
A two-center study in the Journal of the American Heart Association, led by Kubi, tackles a perennial dilemma: when to operate on left-sided infective endocarditis after a stroke [8]. Among 322 surgical patients, postoperative cerebrovascular events fell from about one in five with surgery inside a week to around one in ten with later surgery, and each day of delay modestly lowered the odds. That excess risk, however, was driven by intraparenchymal and subarachnoid hemorrhage and septic emboli. Ischemic strokes showed no meaningful timing effect, and operative mortality was numerically lowest with early surgery, though not significantly so. Meanwhile, about one in ten patients awaiting surgery embolized again. The authors suggest routine delay after ischemic stroke may be unnecessary while a short delay of about a week may be reasonable for hemorrhagic and septic embolic subtypes. This is retrospective, and the hemorrhagic subgroups are small, but it gives phenotype-level data where guidance has often been blunt.
In peripheral intervention, the Journal of the American College of Cardiology published a secondary analysis of the randomized SirPAD trial led by Tsaftaridis, focusing on 597 patients with femoropopliteal disease and no tissue loss [9]. At one year, repeat revascularization of the target lesion occurred in 17 percent with a sirolimus-coated balloon versus 27 percent with an uncoated balloon, about a ten-point absolute reduction, and major adverse limb events were roughly halved. Mortality was similar. The authors stress these findings are descriptive rather than confirmatory, so this is supportive but not definitive evidence for the claudication population.
Rounding out the theme, Nature Reviews Cardiology carries a review by Lee and colleagues on conduction system pacing [10]. It traces the shift from right ventricular apical pacing, with its risk of pacing-induced cardiomyopathy, through His bundle pacing to left bundle branch area pacing, now the dominant modality because of better success and lead stability, with applications from bradycardia to resynchronization. It also introduces Bachmann bundle area pacing as an atrial counterpart that may reduce interatrial delay and possibly atrial fibrillation, an idea the authors flag as needing more evidence.
If you only have time for one paper this week, make it the Coronary Artery Calcium Consortium analysis in JAMA Cardiology [3]. It offers rare multi-decade outcome data on calcification in adults under 45, reopening the question of how early and how intensively prevention should start in people whose risk calculators look reassuring.
Here is what this week's evidence adds up to in Cardiology. First, risk markers carry the most weight where they add absolute risk: premature coronary calcium in young adults and elevated lipoprotein(a) in people with advanced cardiovascular-kidney-metabolic disease both identify meaningfully higher-risk groups, though both datasets are observational and neither tests treatment. Second, four societies now share a life-stage framework for cardiovascular care in girls and women, which is consensus guidance awaiting implementation and outcome data. Third, the hemoglobin rise with SGLT2 inhibitors is real but small and of uncertain clinical meaning, while evidence for any drug in nonobstructive hypertrophic cardiomyopathy remains preliminary. Fourth, retrospective data suggest stroke subtype, not just stroke presence, may govern surgical timing in endocarditis, a hypothesis that deserves prospective confirmation. And fifth, sirolimus-coated balloons showed lower one-year reintervention in claudication, but as a descriptive secondary analysis.
That's your roundup for This Week in Cardiology. The full transcript and references are available on the episode page. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.
If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And if it saves you time, a quick rating in your podcast app helps other physicians find the show.
This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.
Spot something worth flagging?
Get this every week in your podcast app — free.
New cardiology episodes land in your feed automatically — listen on your commute.